Chacruna Institute for Psychedelic Plant Medicines is a registered California 501(c)(3) non-profit organization (EIN 84-3076078). We are a community-oriented organization run by a small staff of experts and enthusiastic volunteers who work to bring education and cultural understanding about psychedelic plant medicines to a wider audience. We promote a bridge between the ceremonial use of sacred plants and psychedelic science and envisage a world where plant medicines and other psychedelics are preserved, protected, and valued as part of our cultural identity and integrated into our social, legal, and health care systems.
Help us to achieve our mission! From our beginnings in 2017, we have stood apart from other psychedelic education and advocacy organizations by pioneering initiatives that support and provide a platform for diverse voices, including women, queer people, people of color, Indigenous people, and the Global South. In efforts to address the lack of diverse representation in the expanding psychedelic landscape, we centered our mission around the empowerment of marginalized voices to foster cultural and political reflections on topics like race, gender, and sexuality in psychedelic science. We believe now more than ever, given the current social and political climate, our work is critical to the future of psychedelic healing for humanity.
Please become a member so that you are able to help Chacruna, yourself, and the world. Support of any amount helps this cause and allows us to provide psychedelic education to anyone who wants to access it.
Dr. Anya Ermakova explains the usages of different vines for the preparation of ayahuasca and gives examples of consequences that have resulted from ayahuasca tourism. People are most familiar with scarcity of plant resources, but there have also been other consequences such as jaguar poaching. Are all the consequences of Ayahuasca tourism negative, or can there be positive aspects to it? Read more in this essay.
Board Certified Psychiatric Pharmacists Dr.’s Ben Malcolm and Kelan Thomas recently published a review article discussing the risks of serotonin syndrome with various serotonergic psychedelics, either alone or in combination with serotonergic antidepressants. In this article, the authors offer a short summary of their main findings.
The relationship between the placebo and psychedelic research is complicated by the psychological aspects of psychedelic therapy. Looking specifically at MDMA trials, Katherine Hendy outlines the history of double-blind studies, how MAPS used placebos in their MDMA trials, and the problems associated with this research methodology.
The rise in popularity of peyote has unfortunately led to overharvesting which consequently poses a great risk for the future of the species. With the increasing need to protect peyote, synthetic mescaline may offer an alternative gateway into this experience that is bereft of issues regarding sustainability. This article summarizes the chemical composition and production of synthetic mescaline.
The incredible states of consciousness that emerge when people consume the psychedelic molecule DMT are characterized by a multiplicity of features. DMT is able...